These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 34898050)

  • 1. How to translate the knowledge of COVID-19 into the prevention of Omicron variants.
    Wang X; Powell CA
    Clin Transl Med; 2021 Dec; 11(12):e680. PubMed ID: 34898050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant.
    Zhou H; Møhlenberg M; Thakor JC; Tuli HS; Wang P; Assaraf YG; Dhama K; Jiang S
    Clin Microbiol Rev; 2022 Sep; 35(3):e0001422. PubMed ID: 35862736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
    Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
    Elife; 2022 Aug; 11():. PubMed ID: 36004719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges of SARS-CoV-2 Omicron Variant and appropriate countermeasures.
    Shao W; Zhang W; Fang X; Yu D; Wang X
    J Microbiol Immunol Infect; 2022 Jun; 55(3):387-394. PubMed ID: 35501267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies.
    Dhama K; Nainu F; Frediansyah A; Yatoo MI; Mohapatra RK; Chakraborty S; Zhou H; Islam MR; Mamada SS; Kusuma HI; Rabaan AA; Alhumaid S; Mutair AA; Iqhrammullah M; Al-Tawfiq JA; Mohaini MA; Alsalman AJ; Tuli HS; Chakraborty C; Harapan H
    J Infect Public Health; 2023 Jan; 16(1):4-14. PubMed ID: 36446204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease severity and efficacy of homologous vaccination among patients infected with SARS-CoV-2 Delta or Omicron VOCs, compared to unvaccinated using main biomarkers.
    Ali AM; Tofiq AM; Rostam HM; Ali KM; Tawfeeq HM
    J Med Virol; 2022 Dec; 94(12):5867-5876. PubMed ID: 36029103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study.
    Lauring AS; Tenforde MW; Chappell JD; Gaglani M; Ginde AA; McNeal T; Ghamande S; Douin DJ; Talbot HK; Casey JD; Mohr NM; Zepeski A; Shapiro NI; Gibbs KW; Files DC; Hager DN; Shehu A; Prekker ME; Erickson HL; Exline MC; Gong MN; Mohamed A; Johnson NJ; Srinivasan V; Steingrub JS; Peltan ID; Brown SM; Martin ET; Monto AS; Khan A; Hough CL; Busse LW; Ten Lohuis CC; Duggal A; Wilson JG; Gordon AJ; Qadir N; Chang SY; Mallow C; Rivas C; Babcock HM; Kwon JH; Halasa N; Grijalva CG; Rice TW; Stubblefield WB; Baughman A; Womack KN; Rhoads JP; Lindsell CJ; Hart KW; Zhu Y; Adams K; Schrag SJ; Olson SM; Kobayashi M; Verani JR; Patel MM; Self WH;
    BMJ; 2022 Mar; 376():e069761. PubMed ID: 35264324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omicron variant of SARS-CoV-2 infection elicits cross-protective immunity in people who received boosters or infected with variant strains.
    Chowdhury S; Chowdhury MS; Chowdhury NS; Chowdhury S; Chowdhury S
    Int J Immunopathol Pharmacol; 2022; 36():3946320221133001. PubMed ID: 36214233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2 B.1.1.529 (Omicron) Variant - United States, December 1-8, 2021.
    CDC COVID-19 Response Team
    MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(50):1731-1734. PubMed ID: 34914670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines.
    Araf Y; Akter F; Tang YD; Fatemi R; Parvez MSA; Zheng C; Hossain MG
    J Med Virol; 2022 May; 94(5):1825-1832. PubMed ID: 35023191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the protective efficacy of approved COVID-19 vaccines against Omicron variants and the prospects for universal vaccines.
    Chen K; Zhang L; Fang Z; Li J; Li C; Song W; Huang Z; Chen R; Zhang Y; Li J
    Front Immunol; 2023; 14():1294288. PubMed ID: 38090587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of SARS-CoV-2 Variants: Implications on Immune Escape, Vaccination, Therapeutic and Diagnostic Strategies.
    Zabidi NZ; Liew HL; Farouk IA; Puniyamurti A; Yip AJW; Wijesinghe VN; Low ZY; Tang JW; Chow VTK; Lal SK
    Viruses; 2023 Apr; 15(4):. PubMed ID: 37112923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial.
    Lee IT; Cosgrove CA; Moore P; Bethune C; Nally R; Bula M; Kalra PA; Clark R; Dargan PI; Boffito M; Sheridan R; Moran E; Darton TC; Burns F; Saralaya D; Duncan CJA; Lillie PJ; San Francisco Ramos A; Galiza EP; Heath PT; Girard B; Parker C; Rust D; Mehta S; de Windt E; Sutherland A; Tomassini JE; Dutko FJ; Chalkias S; Deng W; Chen X; Feng J; Tracy L; Zhou H; Miller JM; Das R;
    Lancet Infect Dis; 2023 Sep; 23(9):1007-1019. PubMed ID: 37348519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.
    Powell AA; Kirsebom F; Stowe J; Ramsay ME; Lopez-Bernal J; Andrews N; Ladhani SN
    Lancet Infect Dis; 2023 Apr; 23(4):435-444. PubMed ID: 36436536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.
    Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR
    JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COVID-19: From emerging variants to vaccination.
    Senevirathne TH; Wekking D; Swain JWR; Solinas C; De Silva P
    Cytokine Growth Factor Rev; 2024 Apr; 76():127-141. PubMed ID: 38135574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 Omicron Variant: Exploring Healthcare Workers' Awareness and Perception of Vaccine Effectiveness: A National Survey During the First Week of WHO Variant Alert.
    Temsah MH; Aljamaan F; Alenezi S; Alhasan K; Alrabiaah A; Assiri R; Bassrawi R; Alhaboob A; Alshahrani F; Alarabi M; Alaraj A; Alharbi NS; Halwani R; Jamal A; Al-Eyadhy A; AbdulMajeed N; Alfarra L; Almashdali W; Fayed A; Alzamil F; Barry M; Memish ZA; Al-Tawfiq JA; Alsubaie S
    Front Public Health; 2022; 10():878159. PubMed ID: 35400032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Wild-type SARS-CoV-2 neutralizing immunity decreases across variants and over time but correlates well with diagnostic testing.
    O'Shea KM; Schuler CF; Chen J; Troost JP; Wong PT; Chen K; O'Shea DR; Peng W; Gherasim C; Manthei DM; Valdez R; Baldwin JL; Baker JR
    Front Immunol; 2023; 14():1055429. PubMed ID: 36845123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of COVID-19 vaccines against SARS-CoV-2 Omicron variants during two outbreaks from March to May 2022 in Quzhou, China.
    Yin Z; Fang Q; Wen T; Zheng C; Fu C; Wang S; Li J; Gong X
    Hum Vaccin Immunother; 2023 Dec; 19(1):2163813. PubMed ID: 36704960
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.